Expanding Commercial Coverage
A majority of patients with commercial insurance have formulary coverage for Taltz*
Taltz will replace Cosentyx®(secukinumab) on the OptumRx National Formulary1
Taltz is now covered on the OptumRx Commercial formularies with the status of preferred IL-17A antagonist across all indications.1,†
There are four national formularies:
- OptumRx Select
- OptumRx Select with Focused UM
- OptumRx Premium
- OptumRx Premium Comprehensive
Taltz is now designated a Tier 3 drug.
Additional Formulary Plan Information
The information in this communication is subject to change without notice.
The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation or warranty of any kind by any plan or insurer referenced herein. This communication is solely the responsibility of Lilly USA, LLC.
The formulary information does not include generic medications in this therapeutic class.
This list may not be an exhaustive list of all plans in your area and the coverage of other plans in your area may vary.
Employers and employer groups may also offer additional benefit designs which may be different than described.
Lilly USA, LLC does not endorse any particular plan. Other product and company names mentioned herein are the trademarks of their respective owners.
The formulary information in this document is for select products that share an approved indication with Taltz® (ixekizumab).Inclusion of a product in this information does not establish clinical comparability of the products for any or all indications and should not be seen as making any claim regarding efficacy or safety.
*Source: Managed Markets Insights & Technology (MMIT), LLC as of August 2019, and is subject to change without notice by a health plan or state. Please contact the plan or state for the most current information. DEFINITION OF COVERAGE: on formulary, but may be subject to restrictions, step edits, tiering, prior authorizations.
†Effective January 1, 2020
Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
SELECT IMPORTANT SAFETY INFORMATION
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.